Related Experiment Video
Updated: Mar 8, 2026
15:53
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
15.6K
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Geraldine O'Sullivan Coyne1, Alice P Chen1, Robert Meehan1
1Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20892, USA.
Drugs
|January 13, 2017
Summary
PARP inhibitors offer effective cancer treatment by blocking DNA repair, especially in tumors with BRCA mutations or other DNA repair defects. This strategy enhances patient selection for PARP inhibitor therapy.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- DNA damage repair is crucial for cell survival and often impaired in cancer.
- Poly(ADP-ribose) polymerase (PARP) proteins are key in repairing single-strand DNA breaks.
- PARP inhibition leverages synthetic lethality in DNA repair-deficient cancer cells.
Purpose of the Study:
- To review clinical trial outcomes of PARP inhibitors (PARPi).
- To discuss companion diagnostic assays for patient selection.
- To explore resistance mechanisms and combination therapies for PARPi.
Main Methods:
- Review of clinical trial data for PARP inhibitors.
- Analysis of diagnostic assay development for patient stratification.
- Literature review of PARPi resistance and therapeutic combinations.
Main Results:
- PARP inhibitors are effective against BRCA-mutated tumors.
- Next-generation sequencing aids in identifying new patient populations susceptible to PARPi.
- Companion diagnostics are being developed for PARPi patient selection.
Conclusions:
- PARP inhibition is a validated strategy for specific cancer types.
- Expanding patient selection beyond BRCA mutations is a key area of research.
- Understanding resistance and developing combination therapies will enhance PARPi efficacy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
01:23Negative Regulator Molecules
38.7K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.7K
02:57piRNA - Piwi-interacting RNAs
7.8K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
7.8K
01:20The Retinoblastoma Gene
4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K